Literature DB >> 17024658

Amplification strategies in MR imaging: activation and accumulation of sensing contrast agents (SCAs).

Manuel Querol1, Alexei Bogdanov.   

Abstract

We review new strategies for the development of Gd3+-based T1-relaxation agents and paramagnetic chemical exchange saturation transfer (PARACEST) "sensing" contrast agents (SCAs) designed specifically to detect small molecules or enzymatic activity in living systems. The first class of agents exhibits molecular "sensing" properties as a result of water coordination sphere effects, cleavage, or synthesis of reactive precursor compounds that recombine with macromolecules with the resultant formation of immobilized or rotationally constrained paramagnetic cations. This effect results in changes of water proton relaxation times. The second class (PARACEST) comprises a family of lanthanide-based paramagnetic compounds suitable for CEST imaging. The need for both types of MR agents is justified by efforts to utilize magnetic resonance imaging (MRI) to visualize fine structures in living tissue, and to increase the molecular specificity of MRI. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17024658     DOI: 10.1002/jmri.20724

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  15 in total

1.  MR-based molecular imaging of the brain: the next frontier.

Authors:  M E de Backer; R J A Nabuurs; M A van Buchem; L van der Weerd
Journal:  AJNR Am J Neuroradiol       Date:  2010-09-23       Impact factor: 3.825

Review 2.  Small animal imaging with magnetic resonance microscopy.

Authors:  Bastiaan Driehuys; John Nouls; Alexandra Badea; Elizabeth Bucholz; Ketan Ghaghada; Alexandra Petiet; Laurence W Hedlund
Journal:  ILAR J       Date:  2008

Review 3.  MRI in rodent models of brain disorders.

Authors:  Aleksandar Denic; Slobodan I Macura; Prasanna Mishra; Jeffrey D Gamez; Moses Rodriguez; Istvan Pirko
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

4.  Targeted signal-amplifying enzymes enhance MRI of EGFR expression in an orthotopic model of human glioma.

Authors:  Mohammed S Shazeeb; Christopher H Sotak; Michael DeLeo; Alexei Bogdanov
Journal:  Cancer Res       Date:  2011-01-18       Impact factor: 12.701

5.  Controlled self-assembling of gadolinium nanoparticles as smart molecular magnetic resonance imaging contrast agents.

Authors:  Gaolin Liang; John Ronald; Yuanxin Chen; Deju Ye; Prachi Pandit; Man Lung Ma; Brian Rutt; Jianghong Rao
Journal:  Angew Chem Int Ed Engl       Date:  2011-05-25       Impact factor: 15.336

6.  In vivo imaging with a cell-permeable porphyrin-based MRI contrast agent.

Authors:  Taekwan Lee; Xiao-an Zhang; Shanta Dhar; Henryk Faas; Stephen J Lippard; Alan Jasanoff
Journal:  Chem Biol       Date:  2010-06-25

Review 7.  Activatable T₁ and T₂ magnetic resonance imaging contrast agents.

Authors:  Chuqiao Tu; Elizabeth A Osborne; Angelique Y Louie
Journal:  Ann Biomed Eng       Date:  2011-02-18       Impact factor: 3.934

8.  Tumor-specific detection of an optically targeted antibody combined with a quencher-conjugated neutravidin "quencher-chaser": a dual "quench and chase" strategy to improve target to nontarget ratios for molecular imaging of cancer.

Authors:  Mikako Ogawa; Nobuyuki Kosaka; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2009-01       Impact factor: 4.774

9.  Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging.

Authors:  Jinyuan Zhou; Jaishri O Blakeley; Jun Hua; Mina Kim; John Laterra; Martin G Pomper; Peter C M van Zijl
Journal:  Magn Reson Med       Date:  2008-10       Impact factor: 4.668

10.  Contrast-enhanced in vivo magnetic resonance microscopy of the mouse brain enabled by noninvasive opening of the blood-brain barrier with ultrasound.

Authors:  Gabriel P Howles; Kristin F Bing; Yi Qi; Stephen J Rosenzweig; Kathryn R Nightingale; G Allan Johnson
Journal:  Magn Reson Med       Date:  2010-10       Impact factor: 4.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.